



Summit Therapeutics plc
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018

Oxford, UK, and Cambridge, MA, US, 14 September 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2018 on 20 September 2018.

Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Company’s website, www.summitplc.com.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for *C. difficile* infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

Tel: 44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Broker)

Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Tel: +44 (0)20 7496 3000

Panmure Gordon (Joint Broker)

Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking

Tel: +44 (0)20 7886 2500

MSL Group (US)

Jon Siegal

Tel: +1 781 684 6557
summit@mslgroup.com

Consilium Strategic Communications (UK)

Mary-Jane Elliott / Jessica Hodgson /
Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-